Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Capítulo 4: histoplasmose Chapter 4: histoplasmosis

Histoplasmose é uma micose sistêmica causada por um pequeno fungo, Histoplasma capsulatum var. capsulatum, cujo habitat é o solo rico em excrementos de pássaros e morcegos. A incidência da histoplasmose é mundial. No Brasil, a doença incide em todas as regiões; porém, o estado do Rio de Janeiro é responsável pelo maior número de microepidemias descritas até hoje. A infecção humana ocorre pela inalação de esporos do H. capsulatum. A forma clínica mais freqüente é a assintomática. Na histoplasmose aguda ou epidêmica, os sintomas são febre alta, tosse, astenia, dor retroesternal, acompanhados de aumento dos linfonodos cervicais, fígado e do baço. Os achados radiológicos mais frequentes são o infiltrado reticulonodular difuso em ambos os pulmões, associados a linfonodomegalias hílares e mediastinais. Na forma pulmonar crônica, o quadro clínico e radiológico é idêntico ao da tuberculose pulmonar do adulto. O diagnóstico da histoplasmose é feito pela identificação do fungo ou crescimento em cultura de escarro ou de material obtido por fibrobroncoscopia. A histopatologia identifica o fungo dentro e fora do macrófago em meio à lesão granulomatosa com ou sem necrose caseosa. A imunodifusão em duplo gel de ágar é o teste sorológico mais fácil e disponível para o diagnóstico imunológico. As formas agudas com sintomas prolongados, as formas disseminadas e a forma pulmonar crônica requerem tratamento. A droga de escolha é o itraconazol.<br>Histoplasmosis is systemic mycosis caused by a small fungus, Histoplasma capsulatum var. capsulatum, whose natural habitat is soil contaminated by bat or bird excrement. The incidence of histoplasmosis is worldwide. In Brazil, the disease is found in all regions; however, the state of Rio de Janeiro is responsible for most of the microepidemics described. Human infection occurs when airborne spores of H. capsulatum are inhaled. The most common clinical presentation is asymptomatic. The symptoms of acute or epidemic histoplasmosis are high fever, cough, asthenia and retrosternal pain, as well as enlargement of the cervical lymph nodes, liver and spleen. The most common radiological findings are diffuse reticulonodular infiltrates in both lungs, as well as hilar and mediastinal lymph node enlargement. In chronic pulmonary histoplasmosis, the clinical and radiological manifestations are identical to those of reinfection with pulmonary tuberculosis. Histoplasmosis is diagnosed by means of the identification or culture growth of the fungus in sputum or fiberoptic bronchoscopy specimens. Histopathological examination reveals the fungus itself within or surrounding macrophages, as well as granulomatous lesions with or without caseous necrosis. Double agar gel immunodiffusion is the most easily used and readily available serologic test for making the immunological diagnosis. Acute histoplasmosis with prolonged symptoms requires treatment, as do the disseminated or chronic pulmonary forms of the disease. The drug of choice is itraconazole

Central nervous system histoplasmosis

10.1097/MD.0000000000010245Medicine (United States)9713e0245